Literature DB >> 17361207

D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.

Marc Hinterberger1, Tanja Reineke, Martina Storz, Walter Weder, Peter Vogt, Holger Moch.   

Abstract

Anti-calretinin antibodies are useful to differentiate adenocarcinomas from malignant mesotheliomas of the lung. Therefore, calretinin expression is rarely reported for sarcomatoid mesotheliomas. Anti-podoplanin antibodies (eg D2-40) react with lymphatic endothelia, Kaposi's sarcoma, lymphangioma and mesotheliomas. For the interpretation of spindle cell lesions of the pleura, knowledge of calretinin and D2-40 expression frequencies in sarcomatoid mesothelioma is desirable. To systematically investigate the sensitivity of calretinin and D2-40 antibodies in epithelioid and sarcomatoid areas of malignant mesotheliomas, a tissue microarray with 341 malignant mesotheliomas, including 112 epithelioid, 46 sarcomatoid and 183 biphasic tumors was constructed. Epithelioid and sarcomatoid differentiated tumor areas were clearly separated within the tissue microarray. Expression of calretinin and D2-40 was separately studied in epithelioid and sarcomatoid areas by immunohistochemistry. Calretinin expression was found in 91% of epithelioid and 57% of sarcomatoid tumor areas. D2-40 immunostaining was present in 66% of the epithelioid and 30% of the sarcomatoid tumor areas. A combination of calretinin and D2-40 increased the sensitivity in epithelioid tumor areas to 0.96 and in sarcomatoid tumor areas to 0.66. These data indicate that a combination of calretinin and D2-40 will improve diagnostic accuracy for spindle cell lesions of the pleura, whereas almost all epithelioid mesotheliomas are identified by calretinin alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361207     DOI: 10.1038/modpathol.3800736

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.

Authors:  Zheng Hua Piao; Xin Cheng Zhou; Jia Yi Chen
Journal:  Virchows Arch       Date:  2021-02-11       Impact factor: 4.064

3.  Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.

Authors:  Mayura Meerang; Karima Bérard; Martina Friess; Byron K Y Bitanihirwe; Alex Soltermann; Bart Vrugt; Emanuela Felley-Bosco; Raphael Bueno; William G Richards; Burkhardt Seifert; Rolf Stahel; Walter Weder; Isabelle Opitz
Journal:  Mol Oncol       Date:  2016-06-25       Impact factor: 6.603

4.  Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx.

Authors:  Gerhard F Huber; Lena Züllig; Alex Soltermann; Matthias Roessle; Nicole Graf; Stephan K Haerle; Gabriela Studer; Wolfram Jochum; Holger Moch; Sandro J Stoeckli
Journal:  BMC Cancer       Date:  2011-06-03       Impact factor: 4.430

5.  Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.

Authors:  Diandian Li; Bo Wang; Hongyu Long; Fuqiang Wen
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.379

6.  Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.

Authors:  Svenja Thies; Martina Friess; Lukas Frischknecht; Dimitri Korol; Emanuela Felley-Bosco; Rolf Stahel; Bart Vrugt; Walter Weder; Isabelle Opitz; Alex Soltermann
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

7.  Podoplanin is a useful prognostic marker and indicates better differentiation in lung squamous cell cancer patients? A systematic review and meta-analysis.

Authors:  Liya Hu; Peng Zhang; Qi Mei; Wei Sun; Lei Zhou; Tiejun Yin
Journal:  BMC Cancer       Date:  2020-05-14       Impact factor: 4.430

8.  Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.

Authors:  Lukas Jyuhn-Hsiarn Lee; Cheng-Kuan Lin; Chih-Hong Pan; Yawen Cheng; Yu-Yin Chang; Saou-Hsing Liou; Jung-Der Wang
Journal:  BMJ Open       Date:  2018-12-09       Impact factor: 2.692

9.  CD74: a new prognostic factor for patients with malignant pleural mesothelioma.

Authors:  C Otterstrom; A Soltermann; I Opitz; E Felley-Bosco; W Weder; R A Stahel; F Triponez; J H Robert; V Serre-Beinier
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

10.  Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2.

Authors:  Taiji Kuwata; Kazue Yoneda; Masataka Mori; Masatoshi Kanayama; Koji Kuroda; Mika K Kaneko; Yukinari Kato; Fumihiro Tanaka
Journal:  Cells       Date:  2020-04-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.